Table 1.

Evidence of Th17-targeted therapy in SLE patients.

Mechanism of Action	Drug	Indications	Reference
IL-17A inhibitor	Secukinumab	Skin lupus (CR), LN (CR), ongoing RCT for LN	[55,79,81,82]
	Ixekizumab	No data in SLE treatment	N/A
IL-17A and F inhibitor	Bimekizumab	No data in SLE treatment	N/A
IL-17 receptor inhibitor	Brodalumab	No data in SLE treatment	N/A
IL-23 and IL-12 inhibitor	Ustekinumab	Failed in RCT	[47]
IL-23 inhibitor	Guselkumab	ongoing RCT for LN	[80]
	Risankizumab	No data in SLE treatment	N/A
	Tildrakizumab	Lupus erythematosus tumidus (CR)	[58]

CR—case report, IL—interleukin, LN—lupus nephritis, N/A—not applicable, RCT—randomized clinical trial.